
News|Articles|October 30, 2025
- Vol.27/No.1
- Volume 27
- Issue 1
Tackling Drug Shortages in Hematologic Oncology Care Requires Nuance and Adaptability
Author(s)Kyle Doherty
Fact checked by: Caroline Seymour
Harry P. Erba, MD, PhD; and Jayastu Senapati, MBBS, discuss the effects of drug shortages in hematologic oncology and how to adapt practice when they arise.
Advertisement
Advertisement
Drug shortages have touched nearly every area of cancer care throughout the years, but their effects can be particularly felt in hematologic oncology, where certain agents are often needed as backbones of treatment and lymphodepleting regimens. In order to best prepare for these inevitable shortages and to minimize their effect on patient care, oncologists must have suitable alternatives in mind that will not compromise the efficacy and safety of a therapeutic regimen.
Related to this article

Mariana C. Stern, PhD, discusses the biggest gaps identified in the 2026 AACR Disparities Progress Report and what oncologists can do to combat them.

The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.

Eric K. Singhi, MD, and Kyle G. Mitchell, MD, MSc, discuss the present and future role of LCT in NSCLC.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Millie Das, MD, outlines how maintenance tarlatamab and lurbinectedin may extend survival beyond current 3-year OS rates in ES-SCLC.
Advertisement
Advertisement



